Catheter Ablation for the Treatment of Paroxysmal Supraventricular Tachycardia

Publisher Website
Google Scholar
Abstract
Catheter Ablation for PSVT. Radiofrequency catheter ablation has evolved into a front‐line curative therapy for patients who have paroxysmal supraventricular tachycardia secondary to Wolff‐Parkinson‐White syndrome, AV nodal reentrant tachycardia, and atrial tachycardia. In patients with accessory pathways, cure rates exceed 90% in almost all anatomic locations. Equally high success rates are noted in patients with atriofascicular pathways and the permanent form of junctional reciprocating tachycardia. Complications secondary to catheter ablation of accessory pathways occur in 1% to 3% of patients and include cardiac perforation, tamponade, AV block, and stroke. In patients with AV nodal reentrant tachycardia, selective slow pathway ablation is curative in over 95% of patients with a very low risk of AV block. Atrial tachycardias originating in both the left and right atria can he successfully ablated in over 80% of patients. Given the overall effectiveness of this procedure, radiofrequency catheter ablation should be considered as front‐line therapy in patients with recurrent or drug‐refractory paroxysmal supraventricular tachycardia. Although an effective therapy, the risks and benefits of this procedure need to be assessed in all patients who are candidates for this procedure.